Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma announces Australian TGA approval of ILUMYA™

Posted On: 2018-09-21 11:59:07

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that Sun Pharma has received the Australian Therapeutic Goods Administration (TGA) approval for its speciality product, ILUMYA™ (tildrakizumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

ILUMYA™ selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of proinflammatory cytokines and chemokines. ILUMYA™ is administered at a dose of 100 mg by subcutaneous injection every 12 weeks after the completion of initial doses at weeks 0 and 4. ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients in ILUMYA™, and in patients with clinically important active infections, e.g. active tuberculosis.

"We are pleased to have received this approval and look forward to bringing ILUMYA™ to dermatologists and patients in Australia," said Hellen De Kloet, Business Head, Western Europe & Australia, Sun Pharma. "We are launching a patient support program to assist patients prescribed with ILUMYA™. The program is designed to supplement the support offered by doctors in their practice or in hospital departments." she added.

The ILUMYA™ patient support program offers self-injection training by a registered nurse, dose reminders, injection consumables and a patient support help line.

ILUMYA™ is one of the key specialty products of Sun Pharma and it was approved by US FDA in March 2018 while the European Commission approved it in September 2018.

In Australia, the number of severe chronic plaque psoriasis patients receiving treatment through the Pharmaceutical Benefit Scheme (PBS) with biologics, increased by more than 60% between 2014 and 2016. However, the number treated was less than 30% of the severely affected population. The total PBS expenditure on biologicals for chronic plaque psoriasis (at published prices) was A$121 million in 20161.

The TGA approval of ILUMYA™ for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program. In the two multicentre, randomized, double-blind, placebo-controlled trials (reSURFACE 1 and reSURFACE 2), 1862 adult patients were enrolled and treated with ILUMYA™ (N=1238), etanercept (N=313) or placebo (N=310). Results from these studies were published in The Lancet in July 2017, with primary endpoints presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress. Both Phase-3 studies met the primary efficacy endpoints, demonstrating significant clinical improvement with ILUMYA™ 100 mg compared to placebo or etanercept when measured by at least 75 percent reduction in baseline psoriasis severity (Psoriasis Area Sensitivity Index or PASI 75) and Physician's Global Assessment (PGA) score of "clear" or "minimal" at week 12 after two doses.

The most common adverse reactions observed with ILUMYA™ in the pooled data from one Phase 2 and two Phase 3 studies in psoriasis patients for the placebo controlled period (16 weeks for the Phase 2 study and 12 weeks for the Phase 3 studies) were nasopharyngitis, headache, and site injection pain. Most adverse reactions were considered mild and no adverse reaction led to discontinuation of treatment in >1% of patients.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.647.3 as compared to the previous close of Rs. 642.3. The total number of shares traded during the day was 596394 in over 9646 trades.

The stock hit an intraday high of Rs. 657 and intraday low of 640.2. The net turnover during the day was Rs. 386413178.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Manappuram Finance Ltd to acquire 100% in Manappuram Comptech & Consultants Ltd

BEML Ltd board declares interim dividend of Rs. 4.50

Power supply restored at Amit Spinning Industries Ltd's factory

Pierer Industrie and Bajaj in discussions for Bajaj to participate at KTM Industries level

PFC signs agreement to acquire majority stake in REC Limited

Infosys and Roland-Garros Partner for Digital Innovation

DIAL awards the Commercial Development Rights at Aerocity, Delhi to a consortium led by M/s Bharti Realty

Bosch Ltd to form JV with Prettl India Pvt Ltd

Frontline Securities Ltd board to consider buy-back on March 26, 2019

IDFC FIRST Bank Ltd has sold 8.37% stake in ARCIL

Sun TV Network Ltd appoints R Mahesh Kumar as MD

CCL Products India Ltd board to consider interim dividend on March 23, 2019

Greenlam Industries Ltd to increase capacity through brownfield expansion

Smt. Sushmita Dasgupta appointed as Government Director of Indian Oil Corporation Ltd

Promoter group entities of Greaves Cotton Ltd to merge

California Software Company Ltd to consider allotment of OCRPS to Chemoil

Adani Transmission Ltd board approves buy-back of 10,000 NCDs

ABans Enterprises Ltd to acquire Abans Jewels Pvt Ltd

HUDCO updates on medium term note programme

Gopala Polyplast Ltd withdraws QIP

Sayaji Hotels Ltd terminates lease agreement with Barbeque-Nationa

GE T&D India Ltd updates on transformer business

Karnataka Bank opens its 839th Branch at Nadugodu - Kateel

Zensar brings 'Experience Digital Returns' focused solutions to Adobe Summit 2019

Topcoder's Crowdsourced Quality as a Service for On-Demand Testing Enables Faster Speeds, Greater Work Volumes for Customers

Krypton Industries Ltd receives order of Rs. 23.10 crores

CG equipped 'Deutsche Bucht' offshore substation topside sails out

Prima Plastics Ltd's JV declares dividend

Asian Oilfield Services receives LOI from Oilmax for contract of Rs. 210 crores for 10 years

Toyota and Suzuki Agree to Start Consideration toward New Collaboration

HFS Research Ranks HGS in the Top 3 for Voice of the customer in survey of more than 300

REC Ltd approves market borrowing programme for 2019-20

Onida launches smart air conditioners ONYXS and GENIO

Alankit Ltd Board approves interim dividend of Rs. 0.20 for 2018-19

Vodafone Idea Ltd board approves terms of rights issue

SBI Life Insurance Company Ltd fixes Apr 4, 2019 as record date for interim dividend

Newgen Positioned as a Strong Performer in Digital Process Automation for Wide Deployments by Top Independent Research Firm

Colgate Palmolive India Ltd fixes Apr 8, 2019 as record date for second interim dividend

Mahindra & Mahindra Financial Services Ltd allots 5000 NCDs worth Rs. 500 crores

The launch of Wealth Qube - 2020 at Intellect User Meet, Dubai

SHARP India Ltd board meeting to approve appointment of Mr. Naoki Hatayama as MD

Indraprastha Gas Ltd announces cessation of two independent directors

SHARP India Ltd announces resignation of MD

China Telecom Global partners with Tata Communications

HCL and Xerox expand Strategic Partnership to accelerate operational Transformation

Jet Airways India Ltd grounds another 6 aircraft

Vikas WSP Ltd updates on US court litigation

Tata Steel Bsl Ltd allots NCRPS worth Rs. 6500 crore to Tata Steel Ltd

IDBI Bank Ltd approves rupee bond borrowing limit of Rs. 4000 crore

Newgen secures another Patent for its invention - Integrated and Automatic Generation of Carbon Credits







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019